FDAnews Device Daily Bulletin

NUVASIVE ANNOUNCES IDE APPROVAL TO BEGIN NEODISC PIVOTAL TRIAL

June 29, 2006
A A

NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today it has received conditional approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin clinical trial enrollment of its NeoDisc cervical disc replacement device.
PR Newswire